The objective was to determine the safety and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD). Summary and Background Data: PNALD can be a lethal complication in children with short bowel syndrome (SBS). ILE based on soybean oil administered with parenteral nutrition (PN) may contribute to its etiology.
P arenteral nutrition (PN) is a life-saving therapy for patients with intestinal failure syndromes, including patients with short bowel syndrome (SBS) due to a variety of congenital or acquired gastro-intestinal (GI) illnesses, as well as those with intractable GI motility problems. In 2002, the National Institute of Diabetes and Digestive and Kidney Diseases estimated that 20,000 individuals in the United States were sustained by PN for intestinal failure. 1 Until the advent of routine use of PN, patients with these conditions commonly died of malnutrition. [2] [3] [4] PN contains both macronutrients (dextrose, fat, crystalline amino acids), and micronutrients (vitamins and trace elements). Fat emulsions are administered to prevent essential fatty acid deficiency (EFAD) and to provide a calorically dense source of nonprotein calories. Despite its life saving properties, PN is associated with hepatic dysfunction, including biochemical and histologic alterations. 5 These abnormalities, which can range from mild elevations of hepatic transaminases to fibrosis and cirrhosis, are likely to progress unless PN is stopped and the patient is able to be maintained on enteral nutrition. The incidence of this oftentimes fatal condition is particularly prevalent in the pediatric population. 6 In one center, 25% of children with SBS went on to develop irreversible hepatic failure. 7 The etiology of PN associated liver disease (PNALD) is unclear and is likely multifactorial. Risk factors for PNALD include prolonged PN use, prematurity, frequent surgical procedures, lack of enteral intake, and sepsis. Cholestasis may be reversible if PN is discontinued and full enteral nutrition (EN) is established. 8 Even partial EN may also be protective. 9 However, treating cholestasis by discontinuing PN is difficult, as it may result in starvation if EN is not absorbed. Other treatment options, including reduction of lipid dose to less than 1 g/kg/d and cyclic PN infusions, have had mixed results. 10 -13 Likewise, pharmacologic interventions such as treatment with metronidazole, ursodeoxycholic acid, or choline, have had moderate success. 14 In refractory hepatic failure in the setting of intestinal failure, liver transplantation (with or without small bowel) remains the only option. Considering that modern graft and patient 5-year survival rates for liver small bowel and isolated small bowel transplants are in the range of 43% to 75% and 57% to 75%, respectively, alternative medical and surgical strategies for SBS and PNALD are still needed. 15, 16 Recent evidence suggests that one major contributing factor that predisposes patients to PNALD may be the composition of the intravenous lipid emulsions. Currently in the United States, lipid emulsions are derived from either soybean oils or a combination of soybean and safflower oils (Table 1) . These oils are rich in omega-6 fatty acids and phytosterols that may contribute to liver injury. 17 We have previously demonstrated in a murine model that a fish oil derived lipid emulsion, in comparison with conventional soybean oil-based products, was able to prevent hepatic steatosis. 18, 19 Unlike soybean oil-based lipid emulsions, fish oil-based lipid emulsions contain high concentrations of the omega-3 fatty acids, docosahexaenoic acid, and eicosapentaenoic acid, the latter being an eicosanoid precursor of the 5 series leukotrienes that are less inflammatory. 20, 21 Moreover, this lipid emulsion also contains arachidonic acid, an omega-6 fatty acid that is also not present in soybean oil-based lipid emulsions. In our 2 previously published preliminary reports, 2 and 18 infants with PNALD were treated with the fish oil-based fat emulsion and serum bilirubin levels normalized. 22, 23 In both studies, patients tolerated this therapy well, and no adverse reactions attributed to its use were observed.
Since the publication of these articles, we have further investigated the safety and efficacy of a fish oil-based lipid emulsion in the reversal of cholestasis. As part of an open label treatment protocol, PN-dependent children with cholestasis had their conventional soy-containing emulsions discontinued and replaced with a fish oil-based emulsion. Outcomes were compared with a contemporary cohort of patients from 1999 to 2006.
METHODS

Patients
Between August 2006 and November 2007, under an open label treatment protocol at Children's Hospital Boston (CHB), 42 infants receiving PN with soybean oil-based emulsions who developed cholestasis were treated with a fish oil-based lipid emulsion and prospectively followed. Eligibility requirements included serum direct bilirubin Ն2 mg/dL and predicted PN duration of Ͼ30 days due to congenital or acquired GI disease. Children with other liver diseases (ie, cystic fibrosis, inborn metabolic errors, hepatitis C) were excluded.
A comparison cohort of controls of 59 infants with SBS, who were PN-dependent and treated at CHB from 1999 to 2006, was screened for eligibility. A total of 49 eligible subjects were identified with 2 consecutive direct bilirubin Ͼ2 mg/dL while on PN that could not be attributed to another cause of hepatic disease.
Study Treatment
In the fish oil cohort, the soybean-based lipid emulsion (Intralipid, Fresenius Kabi, Uppsala, Sweden) was discontinued and treatment with a fish oil-based lipid emulsion (Omegaven, Fresenius Kabi AG, Bad Homburg v.d.h., Germany) was started. Patients received the fish oil-based lipid emulsion at a goal dose of 1 g/kg/d infused in conjunction with PN over 12 to 24 hours. The comparison group received Intralipid, the standard of care lipid emulsion, with fat doses ranging from 1 to 4 g/kg/d.
Study Outcomes
Safety outcomes included biochemical markers of EFAD (defined as triene:tetraene (T/T) ratio Ͼ0.2), dyslipidemia (defined as serum triglyceride levels Ͼ400 mg/dL), and markers of coagulopathy, such as thrombocytopenia and an increase in international normalized ratio (INR) Ͼ2. Efficacy outcomes were based on trajectories of serum levels of direct bilirubin, alanine aminotransferase (ALT), and the rate of cholestasis reversal, defined as the time at which there was 1 of 3 consecutive serum direct bilirubin measurements Յ2 mg/dL. Additionally, we compared the risk of death or liver transplantation between the 2 cohorts. Laboratory values were prospectively measured at approximately weekly intervals. The soybean oil cohort had all available tests retrospectively recorded and measured approximately in weekly or bi-weekly intervals. With the exception of triglyceride and platelet levels, safety outcomes were systematically recorded only in the fish oil cohort.
Laboratory values were retrospectively recorded from baseline (week 0), defined as the date fish oil-based lipid emulsion began for the fish oil cohort, or as the date of the second of 2 consecutive direct bilirubin values Ͼ2 mg/dL for the comparison group. If patients did not have results for the corresponding laboratory test at the baseline week, the closest previous value was used (up to 2 weeks before the baseline time). Patients were followed until 2 weeks after end of PN (so that they would have the opportunity to present with 3 consecutive direct bilirubin Յ2 mg/dL). Deaths or transplants that occurred a few months after cessation of PN were recorded.
Statistical Analysis
Statistically significant differences of baseline characteristics and of frequency of morbidity outcomes (mortality and transplantation) between the 2 groups were assessed via t-tests when reporting means, Wilcoxon tests when reporting medians, and 2 tests (or Fishers exact test) when reporting proportions. Analysis of efficacy of fish oil-based lipid emulsions was based on comparisons between the fish oil and the soybean oil groups of trends over time of direct bilirubin and ALT. Median values (equivalent to the exponential of the mean of the natural logarithm transformed tests) and interquartile ranges over 2-week periods of both tests were plotted from baseline until the time in which at least 3 patients were still under observation. Statistical significance of differences in trends after baseline between the 2 cohorts was tested based on modeling the natural logarithm of the appropriate laboratory test through repeated measures models with generalized estimating equations (exchangeable working correlation matrix). In this paper we report comparisons adjusted for baseline values of the logarithm of the corresponding laboratory test. Although not shown, results based on crude analyses were comparable. Analyses comparing levels and trajectories of efficacy laboratory tests included all enrolled subjects. Efficacy was also based on differences between the 2 cohorts in the time to reverse cholestasis estimated through the product limit estimator of Kaplan-Meier (KM) survival curves and compared through logrank tests. In addition, crude and adjusted hazard ratios were estimated using proportional hazard models. In these last models, we considered adjustments for baseline covariates including duration of PN and baseline direct bilirubin. Although only baseline direct bilirubin was a statistically significant predictor, we reported the adjusted hazard ratio for both covariates. Results adjusted for direct bilirubin only were, however, comparable. For analysis of efficacy based on time to reverse cholestasis, subjects who were still on PN by the end of the study follow-up were censored, as were subjects who died or were transplanted while on PN. All survival analyses were performed including all subjects and excluding subjects who died or underwent transplantation while on PN. Analysis of the safety of fish oil was based on comparisons of the levels and trends over time of safety laboratory tests between the 2 cohorts. To compare mean levels of safety tests, we fitted repeated measure models assuming that levels in the 2 groups were constant over time (ie, including only a term for treatment group). Comparisons of trends over time of safety outcomes were performed similarly to comparisons of trends of efficacy outcomes described in the previous paragraph, ie, by adding an interaction term between observation week and study treatment group in linear regression models adjusted for baseline of the logarithm of the corresponding laboratory tests. These models accounted for correlations within subjects through a generalized estimating equation approach. Additionally, Poisson rates (defined as number of events/number of tests) of triglycerides Ͼ400 mg/dL, INR Ͼ2, and T/T ratio Ͼ0.2 were estimated, and, when data was available in both study groups, differences between the 2 treatment groups were assessed via an over-dispersed Poisson generalized linear model.
All P-values were 2-sided. Analyses were performed in SAS 9.1 (SAS Institute, USA) and S-plus 8 (Insightful, USA).
As Omegaven is not yet licensed for use in the United States, FDA approval was obtained. This study was also approved by the CHB institutional review board. Written informed consent was obtained for all patients receiving the intravenous fish oil-based lipid emulsion.
RESULTS
Children in the fish oil group had younger gestational age than children in the soybean oil cohort (P ϭ 0.046) ( Table 2 ). In addition, children in the fish oil cohort had been exposed to PN for a longer period before enrollment (P ϭ 0.008), were older (P ϭ 0.0002), and presented with more advanced liver disease than children in the soybean oil cohort, as based on direct bilirubin (P ϭ 0.0003) and ALT levels (P ϭ 0.07), although difference in ALT levels were only borderline statistically significant. In summary, the fish oil cohort seemed to have higher risk of liver disease than the soybean oil group.
Patients were followed from baseline until the end of follow-up (due to reversal of cholestasis, cessation of PN, death or end of the observation period, whichever came first) for a median time of 7 weeks (IQR ϭ 4, 14 weeks). Three of 42 patients in the fish oil cohort died, whereas 12 of 49 patients in the soybean oil cohort died; most deaths (3 in the fish oil and 7 in the soybean oil cohort) occurred while on PN. All deaths occurred in patients whose liver 
Efficacy of Fish Oil
In all 91 subjects, while direct bilirubin and ALT markedly decreased over time in the fish oil cohort, they increased over time in the soybean oil cohort (P Ͻ 0.0001 for both tests; Fig. 1 ). Nineteen of 42 patients (45%) in the fish oil cohort and 2 of 49 patients (4.1%) in the soybean oil cohort had their cholestasis reversed while on PN. Among patients who did not die nor were transplanted while on PN, 19 of 38 (50%) reversed cholestasis in the fish oil cohort and 2 of 36 (5.6%) reversed in the soybean oil cohort. Times to reverse cholestasis for the 2 patients in the soybean oil cohort were 3.1 and 9.7 weeks, and the KM median time to reverse cholestasis in the fish oil cohort was 11.7 weeks (IQR ϭ 7.7, 13.9 weeks). The difference in the distribution of time to reverse cholestasis between the 2 cohorts was statistically significant (P Ͻ 0.001) whether analysis excluded patients who died or underwent transplantation while on PN, excluded patients who died or underwent transplantation at any time, or included all patients. Patients who did not die nor underwent transplantation while on PN in the fish oil cohort had 8.6 (hazard ratio ϭ 8.6; 95% CI: 2.0 -37.3) times larger rate of reversing cholestasis than in the soybean oil cohort in crude analysis, and 17.4 (95% CI: 3.7-83) times larger after adjusting for baseline direct bilirubin levels and duration of PN prior to enrollment.
Safety of Fish Oil
The occurrence of undesirable safety outcomes in patients receiving fish oil-based lipid emulsions was lower than in the soybean oil cohort. Based on triglyceride levels above 400 mg/dL, the rate of hypertriglyceridemia in patients receiving the fish oilbased lipid emulsion was lower than in patients receiving the soybean oil-based lipid emulsion-a total of 2 episodes of hypertriglyceridemia occurred in 2 patients after baseline in the fish oil cohort, and 56 events occurred in 12 children in the soybean oil cohort (Table 3) . Also, triglyceride levels in the fish oil cohort were lower (P ϭ 0.0002) and declined faster than those in the soybean oil cohort, and differences in level and trends were statistically significant (P Ͻ 0.0001; Fig. 2A ). Based on T/T ratio, 2 patients receiving the fish oil-based lipid emulsion displayed biochemical evidence of EFAD (T/T ratio Ͼ0.2) on 3 occasions. A review of the events showed that these patients had had their lipid emulsion held or interrupted due to access or fluid issues, further demonstrating the need to ensure that a minimum dose of 1 g/kg/d is administered (data not shown). No comparisons in the incidence of EFAD between the fish oil and soybean oil cohorts could be performed, since T/T ratio was not measured in the soybean oil cohort.
With regards to coagulopathy markers, platelet counts also increased with time in the fish oil cohort in contrast to the soybean oil cohort, suggesting a possible resolution of the liver disease (P Ͻ 0.0001; Fig. 2C ). The mean INR trajectory was constant in the fish oil cohort, fluctuating between 1.10 and 1.25 at all times, whereas it seemed to increase in the soybean oil cohort, fluctuating between 1.06 and 5.90 at all times. However, differences in trends over time between the 2 study groups were not statistically significant, possibly due to fact that INR levels between the 2 cohorts started to dissociate after week 20 (P ϭ 0.35; Fig. 2D ).
DISCUSSION
Infants, particularly premature infants, may survive without a lifelong dependence on PN with as little as 11 cm of initial bowel length, due in part to rapidly growing bowel and adaptation during this time. 24 However, in the PN dependent infant, hepatic injury frequently occurs before bowel adaptation and growth is complete and full EN intake has been achieved. Therefore, the goal is to develop an effective nutritional regimen that allows for bowel growth and adaptation before the onset of end stage liver disease. The significance of such a treatment strategy are considerable given the fact that PNALD has a mortality rate as high as 90% in those children unable to be weaned off PN within a year of diagnosis. 25 Our results suggest that a fish oil-based lipid emulsion may reverse PNALD when used in place of standard soybean oil-based lipid emulsions. The experimental fish oil cohort reversed cholestasis, as measured by decrease in direct bilirubin, more frequently and more rapidly than the comparison soybean oil cohort. Previous experience suggests that in most instances, reversal of cholestasis could only occur after PN is discontinued and full EN has been established.
The etiology of PNALD may be a result of soybean oil-based lipid emulsions, secondary to pro-inflammatory metabolites of omega-6 fatty acids, 26 coupled with a decreased hepatic clearance of the parenteral lipid. 27 Unlike fish oil-based lipid emulsions, soybean oil-based lipid emulsions contain phytosterols (eg, stigmasterol, b-sitosterol, and campesterol) that are linked with impairment of biliary secretion. 28 Past and very recent studies have suggested that phytosterols may be the "hepatotoxic" or "cholestatic" component of soybean oil-based lipid emulsions. This multitude of factors results in a cholestatic, steatotic liver that is particularly susceptible to inflammatory insults (eg, bloodstream infections, surgery, hepatotoxic medications). 29 In turn, repeated liver injuries result in fibrosis, cirrhosis, and progress to end-stage liver disease. A fish oil-based lipid emulsion addresses these problems on several fronts.
Omega-3 fatty acid metabolites present in fish oil are less involved in the inflammatory response 26 and animal models have shown that parenteral fish oil does not impair biliary secretion and may prevent steatosis. 19, 30, 31 Comparisons based on a historical cohort could result in bias. Since previous medical records were less complete, more follow-up data was missing in this group. A delay in time to reverse cholestasis could result from missing bilirubin measurements and result in overestimating the effect of the fish oil-based lipid emulsion. To minimize these biases, bilirubin levels were imputed for certain data points. It is unlikely that worse outcomes in the soybean oil cohort were due to poorer management of care, resultant from historical trends. For example, mortality in the soybean oil cohort, uniformly recorded over time, did not increase and was consistent with experiences from other centers. Furthermore, the rate of increase of bilirubin in both groups when all patients were receiving soybean oil-based lipid emulsions was similar. Underestimation of fish oilinduced reversal of cholestasis could result from enrollment under a compassionate protocol, because the patients were more severely ill and were at higher risk due to several prognostic factors, including gestational age. The impact of these biases should be reduced when estimating adjusted effect in multiple regressions. Although clinical improvement in the fish oil cohort could theoretically be in part due to lower doses of fish oil (1 g/kg/d) than what is typically used in pediatric PN, several patients in the fish oil cohort developed cholestasis while receiving only 1 g/kg/d of soybean oil. Although the fear of developing EFAD from the use of the fish oil-based lipid emulsion as monotherapy is real when doses less than 1 g/kg/d are used, adding back soybean oil at a dose of 1 g/kg/d in combination with fish oil-based lipid emulsion at 1 g/kg/d may actually hinder reversal of cholestasis as demonstrated in recently published papers. 32, 33 In fact, in one case series, soybean oil-based lipid emulsions were stopped when patients failed to improve. 32, 34 This practice of combining the 2 products may have even contributed to the progression of liver disease as evidenced by the need for 3 of 12 patients to undergo a liver-intestine transplant. Although 9 of 12 patients did experience complete and sustained resolution of their cholestasis, 5 
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Parenteral Fish Oil for PNALD of 9 patients had the soybean oil-based lipid emulsion stopped and required rescue with the fish oil-based lipid emulsion given as monotherapy to see improvement. Only 4 of 12 patients' cholestasis resolved on the combination therapy. Similar to our experience, no patients in that case series died due to PNALD. Moreover, it may be possible that even higher doses of fish oil-based lipid emulsion could be used, although we have not explored this possibility. 33 In conclusion, we have demonstrated that utilization of a fish oil-based lipid emulsion in infants dependent on PN as a lifesustaining measure may reverse cholestasis and fatal liver disease. More importantly, we have not observed any deleterious side effects of treatment. These benefits may be due to the absence of soybean oil, the pharmacologic effects of fish oil, the reduction of lipid dose, the ability to increase enteral nutrition, or a combination of all these factors. Ideally, a prospective randomized controlled trial comparing fish oil-based lipid emulsions to soybean oil-based lipid emulsions in the treatment of established PNALD should be conducted, but this type of study would be difficult to conduct as some may consider it unethical to perform a study where children with preexisting PN liver injury could potentially be randomized to a treatment group in which they would continue to receive a soybean-oil based lipid emulsion. A prospective randomized trial is underway at our institution to assess the efficacy of fish oil-based emulsions in the prevention of cholestasis in which subjects are randomized to either conventional soybean oil-based lipid emulsion or fish oil-based lipid emulsion at a goal dose of 1 g/kg/d at the start of their PN course. oral supplement diets, and perhaps claims for their importance have been somewhat exaggerated at times. However, in this instance, you show quite clearly that they have a positive effect in reversing severe changes in the liver caused by whatever parenteral diet the patients had been receiving until then. I also know from reading your manuscript that you did preliminary work in rats and mice before this clinical study to justify the use of omega-3 fatty acid-based lipid emulsions in your pediatric patients who developed PNALD while receiving TPN. For 20 or 30 years, people have talked about "designer" or "structured" lipid emulsions in which one could use the basic 3 carbon atoms of a glycerol molecule and add different fatty acids to each of the 3 carbons and come up with a mixture of omega-3s and 6s and other fatty acids in an emulsified parenteral infusion that when metabolized by the body would yield substrates ideal for patient growth, development and maintenance of normal structure and function. We are finally on our way to attacking this vexing PNALD problem. I have been troubled by the clinical use of soybean oil-based lipid emulsions from the beginning. Nobody ever insisted that the previous emulsions made from cotton seed oil should be balanced. Nobody ever proved that soybean oil emulsions were balanced, and, indeed, they are not. We enthusiastically infused intravenous fat. Then we pushed it to excessive doses from 1, 2, 3, 4 g/kg body weight per day, not only to satisfy essential fatty acid requirements, but also to provide additional calories. I think you are finding that even at 1 g/kg/d of the omega-3 fatty acids, you are not observing fatty acid deficiency, and you also do not induce parenteral nutrition-associated liver disease in these children. Indeed, you reverse it. These are spectacular results that are very gratifying and encouraging. The conundrum is if you give what you think the patient needs in the form of the emulsions we now have, we risk PNALD and liver failure, which may progress to death directly or even after liver transplant. If you stop the TPN and the patients do not have enough gut to nourish themselves by enteral nutrition, they will starve to death. Therefore, in either case the patient will suffer, and the ultimate endpoint will be death. My first question is, whether we are overloading the patient similar to inducing an overfeeding syndrome, when you administer too much TPN to an adult, or whether there is a specific toxicity. Is there any data to show one or the other might be the mechanism by which the liver is damaged? Have you or has anyone else conducted any studies on blood flow measurements to the liver? Obviously when you feed the patient, you increase the flow of blood to the portal venous circulation from the intestine into the liver in contrast to NPO when there will be shifts in hepatic artery versus portal vein flow. If your omega-3s fatty acids are not the complete answer, would you consider at some point doing a reverse cava portal shunt to increase blood flow to the portal vein? The last comment I want to make is that all of the fat emulsions we use now are not physiologic. They are treated as foreign bodies by the cells of the reticulo-endothelial system that engulf the fat globules, break them down intracellularly and then release the free fatty acids into the circulation. To provide physiologic forms of fat by vein, we need to use micelles. Thus, another limb to one of your future studies might be to prepare physiologic fat emulsions using fatty plasma obtained from compatible donors. We did that in the first few babies grown on TPN when fat emulsions were not available in this country to support them. It would be interesting to see what effect the micelles might have versus the way we have been using fats in TPN formulations.
DR. MARK PUDER (BOSTON, MASSACHUSETTS):
The toxicity of soybean emulsions contributes to the liver injury but is not the only problem. These children tend to suffer from numerous inflammatory problems that include translocation of the bacteria and line sepsis.
Even the central line itself is inflammatory. Part of the problem may be that Intralipid is so rich in omega-6 fatty acids that it produces a pro-inflammatory situation for the infant. When we administer Omegaven, we do follow the C-reactive protein levels in all patients. After the C-reactive protein normalizes, so goes the bilirubin and the liver function. The etiology is probably in large part due to inflammation. To answer the blood flow question, it is interesting that you actually asked that question. We did perform some LPS studies in mice. The animals that received LPS and were fed omega 3s in their diet appear to have increased blood flow to their livers in the presence of sepsis. As far as a shunt, I have not thought about performing a shunt. This will not be the ideal lipid emulsion. We are performing a large number of studies to find out what components are needed to make the optimal lipid emulsion in animals. We hope to develop an improved intravenous lipid emulsion and possibly administer it to patients sometime in the future.
DR. THOMAS F. TRACY, JR. (PROVIDENCE, RHODE ISLAND): You keep indicating this is an anti-inflammatory model in terms of your experimental work and certainly in your clinical outcome. But can you give us some specific data on the kind of things that we would see in practice that would indicate that you have indeed overcome inflammation? For example, you alluded to the sepsis that these infants and children usually suffer and wonder if you ameliorated it. Were their decreases in the overall numbers of catheter infections or the treatment required based on assumed catheter infections? In terms of biological mechanism, I know it is hard to understand. For many of us studying liver repair, we look at it as an inflammatory process and now this work shows that you can use very active antiinflammatory treatment and still repair the liver. Did you notice any other markers like GTT falling before bilirubin falling that indicates actual biliary remodeling or any other proposed indicators of the mechanisms responsible for your excellent outcomes? DR. MARK PUDER (BOSTON, MASSACHUSETTS): The bilirubin levels, GGT, and other liver enzymes tend to elevate initially. Once the bilirubin normalizes, the enzymes decrease. Patients receiving Omegaven have a decrease in infections to almost half the rate seen when the same patients are on Intralipid. This may be due to the liver's improving ability to clear infections. We do look at C-reactive protein levels, as I mentioned earlier. Once the C-reactive protein levels normalize, the liver improves. The mechanism may be due to the antiinflammatory effect and also improvement of bile flow. Improvement in bile flow has been shown in piglet studies. We did have some patients who had biopsies after the cholestasis resolved. The pathologist often describes some fibrosis or even extensive fibrosis and as bland without inflammatory infiltrate when the liver is compared with a previous biopsy. We do see an antiinflammatory effect clinically.
DR. ROBERT J. TOULOUKIAN (NEW HAVEN, CONNECTICUT): As you indicated, these are a fairly diverse group of patients who have as the common denominator TPN cholestasis, but they include patients with intestinal dysmotility as well as the short gut patients, the pre-term patients, and the full-term patients. Can you tease out from your data those patients that are easiest to treat and the ones that are more difficult to treat? Upon reaching what you consider to be satisfactory total bilirubin levels, do you continue with your omega-3 protocol or do you attempt to convert any of these patients back to their original soybean therapy? Was there any baby that developed a rebound of cholestasis on continued long-term TPN while on this protocol? I think you answered a question earlier having to do with whether or not the effect was primarily on the liver cell first or on the secretory cycle for conjugated bilirubin. Could you extrapolate on that? Finally, I think for further studies, is this Annals of Surgery • Volume 250, Number 3, September 2009 Parenteral Fish Oil for PNALD truly just an antiinflammatory effect or does omega-3 actually impact on the ability of the liver cell to secrete conjugated bilirubin; to excrete it into the bile duct?
DR. MARK PUDER (BOSTON, MASSACHUSETTS): The patients that are easiest to treat are the ones with microvillus inclusion disease. We have 2 of them, and they both resolved their cholestasis in 3 weeks. It does not seem to matter whether they are eating or not. The patient with a very short bowel is the most difficult to treat. We do not know what makes a patient respond quicker or improve at all. Even patients that have end-stage liver disease, meaning and elevated INR, can sometimes turn around, but some patients with just severe hepatic fibrosis and reversal of portal flow may not get better. There are very few patients in this category out of the 115 patients.
We do not have enough treatment failures to find a trend. We did notice that these patients have had an enormous number of transfusions and are from other institutions. All patients from our institution reversed their cholestasis. Some infants receive up to 50 blood transfusions, which leads us to the last question you asked about transporters. We are looking at knockouts in transporters that are important in the transport of bile acids. The omega-3s seem to reduce liver injury in these animals and data is preliminary. Every patient removed from the transplant list that is permanently on Omegaven or has been on it for several years has avoided transplantation. No patients have been relisted. There are 2 patients who resumed soybean oil. They are on very low dose soybean oil and none of those patients have redeveloped PN cholestasis.
